A series of cardiometabolic-related news items have been observed from: AstraZeneca, Novo Nordisk, Vertex, and One Health Biosensing. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Metsera announced positive topline results from its Ph1 clinical trial of MET-097, its ultra-long-acting injectable GLP-1RA (view press release); and Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, testified at the Senate Committee on Health, Education, Labor, and Pensions (HELP) hearing titled, “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High Prices for Ozempic and Wegovy?” (view broadcast here). Below, FENIX provides insight into Metsera’s first obesity data readout as well as initial thoughts on the Senate HELP committee hearing.
A series of cardiometabolic-related news items have been observed from Lilly, Insulet, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
Novo Nordisk hosted its Q2 ’24 earnings call (press release; slides) and provided updates across its CVRM portfolio. Importantly, Novo disclosed it has withdrawn the STEP HFpEF sNDA and it discontinued development of its QM GLP/GIP dual agonist, among other updates. FENIX will cover Novo’s London Q2 ’24 earnings call tomorrow, August 8, 2024. Below, FENIX provides highlights and insights from the Q2 ’24 earnings call.
Findings from a University of Oxford study published in the Lancet demonstrated Ozempic decreased the risk of developing dementia by 48% vs. sitagliptin after one year and protected against other cognitive problems (view article; view study). For context, the study evaluated 12-month neurological and psychiatric outcomes of semaglutide vs. sitagliptin, empagliflozin, and glipizide using electronic health records. Below, FENIX provides highlights and insights into the study’s findings.
A series of cardiometabolic-related news items have been observed from Roche, Lilly, Pfizer, and the FTC. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Dexcom, US House of Representatives, and Esperion. Below, FENIX provides highlights and insights for the respective news items.
On the final day of the ADA 2024 conference, nine cardiometabolic-related news items have been observed from Novo Nordisk, Adipo Therapeutics, Trinity Biotech, Alnylam, Viking, Teva, Teladoc Health, and CHMP. Below, FENIX provides context and analysis for the announcements, including thoughts on the potential FLOW label.
Three cardiometabolic-related news items have been observed: Verily launched a new AI-powered CVRM virtual care program (view press release); Bernie Sanders is moving to subpoena Novo Nordisk surrounding Wegovy and Ozempic prices (view article); and FDA approved the Farxiga pediatric T2DM indication (view press release). Below, FENIX provides highlights and insights into the respective news items.
A series of cardiometabolic-related news items have been observed from Syntis Bio, Akero Therapeutics, Merck, and Nanexa AB. Below, FENIX provides highlights and insights for the respective news items.